Literature DB >> 23665223

p53 DNA binding cooperativity is essential for apoptosis and tumor suppression in vivo.

Oleg Timofeev1, Katharina Schlereth, Michael Wanzel, Attila Braun, Bernhard Nieswandt, Axel Pagenstecher, Andreas Rosenwald, Hans-Peter Elsässer, Thorsten Stiewe.   

Abstract

Four molecules of the tumor suppressor p53 assemble to cooperatively bind proapoptotic target genes. The structural basis for cooperativity consists of interactions between adjacent DNA binding domains. Mutations at the interaction interface that compromise cooperativity were identified in cancer patients, suggesting a requirement of cooperativity for tumor suppression. We report on an analysis of cooperativity mutant p53E177R mice. Apoptotic functions of p53 triggered by DNA damage and oncogenes were abolished in these mice, whereas functions in cell-cycle control, senescence, metabolism, and antioxidant defense were retained and were sufficient to suppress development of spontaneous T cell lymphoma. Cooperativity mutant mice are nevertheless highly cancer prone and susceptible to different oncogene-induced tumors. Our data underscore the relevance of DNA binding cooperativity for p53-dependent apoptosis and tumor suppression and highlight cooperativity mutations as a class of p53 mutations that result in a selective loss of apoptotic functions due to an altered quaternary structure of the p53 tetramer.
Copyright © 2013 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23665223     DOI: 10.1016/j.celrep.2013.04.008

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  41 in total

Review 1.  p53, a translational regulator: contribution to its tumour-suppressor activity.

Authors:  V Marcel; F Catez; J-J Diaz
Journal:  Oncogene       Date:  2015-03-02       Impact factor: 9.867

Review 2.  Senescence and apoptosis: dueling or complementary cell fates?

Authors:  Bennett G Childs; Darren J Baker; James L Kirkland; Judith Campisi; Jan M van Deursen
Journal:  EMBO Rep       Date:  2014-10-13       Impact factor: 8.807

3.  The p53 Target Gene SIVA Enables Non-Small Cell Lung Cancer Development.

Authors:  Jeanine L Van Nostrand; Alice Brisac; Stephano S Mello; Suzanne B R Jacobs; Richard Luong; Laura D Attardi
Journal:  Cancer Discov       Date:  2015-03-26       Impact factor: 39.397

Review 4.  The Paradox of p53: What, How, and Why?

Authors:  Yael Aylon; Moshe Oren
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

Review 5.  Deconstructing networks of p53-mediated tumor suppression in vivo.

Authors:  Alyssa M Kaiser; Laura D Attardi
Journal:  Cell Death Differ       Date:  2017-11-03       Impact factor: 15.828

Review 6.  Senescent cells: an emerging target for diseases of ageing.

Authors:  Bennett G Childs; Martina Gluscevic; Darren J Baker; Remi-Martin Laberge; Dan Marquess; Jamie Dananberg; Jan M van Deursen
Journal:  Nat Rev Drug Discov       Date:  2017-07-21       Impact factor: 84.694

7.  p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosis.

Authors:  Nicholas W Fischer; Aaron Prodeus; David Malkin; Jean Gariépy
Journal:  Cell Cycle       Date:  2016-10-18       Impact factor: 4.534

Review 8.  Drugging the p53 pathway: understanding the route to clinical efficacy.

Authors:  Kian Hoe Khoo; Khoo Kian Hoe; Chandra S Verma; David P Lane
Journal:  Nat Rev Drug Discov       Date:  2014-03       Impact factor: 84.694

9.  PUMA promotes apoptosis of hematopoietic progenitors driving leukemic progression in a mouse model of myelodysplasia.

Authors:  A A Guirguis; C I Slape; L M Failla; J Saw; C S Tremblay; D R Powell; F Rossello; A Wei; A Strasser; D J Curtis
Journal:  Cell Death Differ       Date:  2016-01-08       Impact factor: 15.828

10.  Inactivation of Mdm2 restores apoptosis proficiency of cooperativity mutant p53 in vivo.

Authors:  Boris Klimovich; Thorsten Stiewe; Oleg Timofeev
Journal:  Cell Cycle       Date:  2019-11-21       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.